Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

H Zhang, C Qin, C An, X Zheng, S Wen, W Chen, X Liu… - Molecular cancer, 2021 - Springer
Abstract The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and
Jennifer Doudna for the development of the Clustered regularly interspaced short …

Regulating tumor suppressor genes: post-translational modifications

L Chen, S Liu, Y Tao - Signal transduction and targeted therapy, 2020 - nature.com
Tumor suppressor genes cooperate with each other in tumors. Three important tumor
suppressor proteins, retinoblastoma (Rb), p53, phosphatase, and tensin homolog deleted …

Targeting ARID1A mutations in cancer

J Mullen, S Kato, JK Sicklick, R Kurzrock - Cancer treatment reviews, 2021 - Elsevier
Genes encoding SWI/SNF chromatin remodeling complex subunits are collectively mutated
in approximately 20% of human cancers. ARID1A is a SWI/SNF subunit gene whose protein …

[HTML][HTML] Whole-genome and transcriptome analysis enhances precision cancer treatment options

E Pleasance, A Bohm, LM Williamson, JMT Nelson… - Annals of …, 2022 - Elsevier
Background Recent advances are enabling delivery of precision genomic medicine to
cancer clinics. While the majority of approaches profile panels of selected genes or hotspot …

Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function

L Gao, ZX Wu, YG Assaraf, ZS Chen, L Wang - Drug Resistance Updates, 2021 - Elsevier
The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …

Annexin A1 as a regulator of immune response in cancer

TG Araújo, STS Mota, HSV Ferreira, MA Ribeiro… - Cells, 2021 - mdpi.com
Annexin A1 is a 37 kDa phospholipid-binding protein that is expressed in many tissues and
cell types, including leukocytes, lymphocytes and epithelial cells. Although Annexin A1 has …

Targeting NRF2 to treat cancer

J Sivinski, DD Zhang, E Chapman - Seminars in cancer biology, 2021 - Elsevier
NRF2 is a basic leucine zipper (bZip) transcription factor that is the master regulator of redox
homeostasis. Under basal conditions, the cellular level of NRF2 is low due to a …

[HTML][HTML] Therapeutic strategies for targeting CDKN2A loss in melanoma

IZM Kreuger, RC Slieker, T van Groningen… - Journal of Investigative …, 2023 - Elsevier
Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event
driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss …

Molybdenum Diphosphide Nanorods with Laser‐Potentiated Peroxidase Catalytic/Mild‐Photothermal Therapy of Oral Cancer

M Qian, Z Cheng, G Luo, M Galluzzi, Y Shen… - Advanced …, 2022 - Wiley Online Library
Chemodynamic therapy (CDT) is an emerging treatment that usually employs chemical
agents to decompose hydrogen peroxide (H2O2) into hydroxyl radical (• OH) via Fenton or …

A workflow to study mechanistic indicators for driver gene prediction with Moonlight

M Nourbakhsh, A Saksager, N Tom… - Briefings in …, 2023 - academic.oup.com
Prediction of driver genes (tumor suppressors and oncogenes) is an essential step in
understanding cancer development and discovering potential novel treatments. We recently …